[1]
|
Alvares, C.A., Svidzinski, T.I.E. and Consolaro, M.E.L. (2007) Vulvovaginal Candidiasis: Susceptibility Factors of the Host and Virulence of the Yeasts. Jornal Brasileiro de Patologia e Medicina Laboratorial, 43, 319-327. http://dx.doi.org/10.1590/S1676-24442007000500004
|
[2]
|
Rosa M.I. and Rumel, D. (2004) Fatores associados a candidíase vulvovaginal: Estudo exploratório. Revista Brasileira de Ginecologia e Obstetrícia, 26, 65-70. http://dx.doi.org/10.1590/S0100-72032004000100010
|
[3]
|
Rylander, E., Berglund, A.L., Krassny, C. and Petrini, B. (2004) Vulvovaginal Candida in a Young Sexually Active Population: Prevalence and Association with Oro-Genital Sex and Frequent Pain at Intercourse. Sexually Transmitted Infections, 80, 54-57. http://dx.doi.org/10.1136/sti.2003.004192
|
[4]
|
Caiyan, X., Weiyuan, Z., Minghui, W. and Songwen, Z. (2012) Prevalence and Risk Factors of Lower Genital Tract Infections among Women in Beijing, China. The Journal of Obstetrics and Gynaecology Research, 38, 310-315.
|
[5]
|
Correa, P.R., David, P.R.S., Peres, N.P., Cunha, K.C. and Almeida, M.T.G. (2009) Phenotypic Characterization of Yeasts Isolated from the Vaginal Mucosa in Adult Women. Revista Brasileira de Ginecologia e Obstetrícia, 31, 177-181. http://dx.doi.org/10.1590/S0100-72032009000400004
|
[6]
|
Gunther, L.S., Martins, H.P., Gimenes, F., Abreu, A.L., Consolaro, M.E. and Svidzinski, T.I. (2014) Prevalence of Candida albicans and Non-Albicans Isolates from Vaginal Secretions: Comparative Evaluation of Colonization, Vaginal Candidiasis and Recurrent Vaginal Candidiasis in Diabetic and Non-Diabetic Women. Sao Paulo Medical Journal, 132, 116-120. http://dx.doi.org/10.1590/1516-3180.2014.1322640
|
[7]
|
Mnichowska-Polanowskai, M., Wojciechowska-Koszko, I., Klimowicz, B., et al. (2013) Endogenous or Exogenous Origin of Vaginal Candidiasis in Polish women? Polish Journal of Microbiology, 82, 532-543.
|
[8]
|
Corsello, S. (2003) An Epidemiological Survey of Vulvovaginal Candidiasis in Italy. European Journal of Obstetrics & Gynecology and Reproductive Biology, 110, 66-72. http://dx.doi.org/10.1016/S0301-2115(03)00096-4
|
[9]
|
Douglas, L.J. (2003) Candida Biofilms and Their Role in Infection. Trends in Microbiology, 11, 30-36. http://dx.doi.org/10.1016/S0966-842X(02)00002-1
|
[10]
|
Pádua, R.A.F., Guilhermetti, E. and Svidzinski, T.I.E. (2003) In Vitro Activity of Antifungal Agents on Yeasts Isolated from Vaginal Secretion. Acta Scientiarum, Health Sciences, 25, 51-54.
|
[11]
|
Ferrazza, M.H.S.H., Maluf, M.L.F., Consolaro, M.E.L., Shinobu, C.S., Svidzinski, T.I.E. and Batista, M.R. (2005) Characterization of Yeasts Isolated from the Vagina and Their Association with Vulvovaginal Candidiasis in Two Cities in Southern Brazil. Revista Brasileira de Ginecologia e Obstetrícia, 27, 58-63. http://dx.doi.org/10.1590/S0100-72032005000200003
|
[12]
|
Spacek, J., Buchta, V., Jilek, P. and Forstl, M. (2007) Clinical Aspects and Luteal Phase Assesment in Patients with Recurrent Vulvovaginal Candidiasis. European Journal of Obstetrics & Gynecology and Reproductive Biology, 48, 165-171.
|
[13]
|
Hong, E., Dixit, S., Fidel, P.L., Bradford, J. and Fischer, G. (2014) Vulvovaginal Candidiasis as a Chronic Disease: Diagnostic Criteria and Definition. Journal of Lower Genital Tract Disease, 18, 31-38. http://dx.doi.org/10.1097/LGT.0b013e318287aced
|
[14]
|
Ehrstrom, S.M., Kornfeld, D., Thuresson, J. and Rylander, E. (2005) Signs of Chronic Stress in Women with Recurrent Candida Vulvovaginitis. American Journal of Obstetrics & Gynecology, 193, 1376-1381. http://dx.doi.org/10.1016/j.ajog.2005.03.068
|
[15]
|
Fleming, D.C. (2003) Hormonal Contraception Can Suppress Natural Antimicrobial Gene Transcription in Human Endometrium. Fertility and Sterility, 79, 856-863. http://dx.doi.org/10.1016/S0015-0282(02)04930-0
|
[16]
|
Ziarrusta, G.B. (2002) Vulvovaginitis Candidiásica. Revista Iberoamericana de Micología, 19, 22-24.
|
[17]
|
Barbedo, L.S. and Sgarbi, D.B.G. (2010) Candidíase. DST. Jornal Brasileiro de Doencas Sexualmente Transmissíveis, 22, 22-38.
|
[18]
|
Ding, J., Chou, Y.Y. and Chang, T.L. (2009) Defensins in Viral Infections. Journal of Innate Immunity, 1, 413-420. http://dx.doi.org/10.1159/000226256
|
[19]
|
Vega, A., Ventura, I. and Chamorro, C. (2011) Neutrophil Defensins: Their Possible Role in Allergic Asthma. Journal of Investigational Allergology and Clinical Immunology, 21, 38-43.
|
[20]
|
Suarez-Carmona, M., Hubert, P., Delvenne, P. and Herfs, M. (2015) Defensins: “Simple” Antimicrobial Peptides or Broad-Spectrum Molecules? Cytokine & Growth Factor Reviews, 26, 361-70. http://dx.doi.org/10.1016/j.cytogfr.2014.12.005
|
[21]
|
Smith, J.G. and Nemerow, G.R. (2008) Mechanisms of Adenovirus Neutralization by Human Alpha Defensins. Cell Host Microbe, 3, 11-19. http://dx.doi.org/10.1016/j.chom.2007.12.001
|
[22]
|
Wehkamp, J., Wang, G., Kübler, I., et al. (2007) The Paneth Cell Alpha-Defensin Deficiency of Ileal Crohn’s Disease Is Linked to Wnt/Tcf-4. The Journal of Immunology, 179, 3109-3118. http://dx.doi.org/10.4049/jimmunol.179.5.3109
|
[23]
|
Jurevic, R.J., Bai, M., Chadwick, R.B., White, T.C. and Dale, B.A. (2003) Single-Nucleotide Polymorphisms (SNPs) in Human Beta-Defensin 1: High-Throughput SNP Assays and Association with Candida Carriage in Type 1 Diabetics and Nondiabetics Controls. Journal of Clinical Microbiology, 41, 90-96. http://dx.doi.org/10.1128/JCM.41.1.90-96.2003
|
[24]
|
Vylkova, S., Nayyar, N., Li, W. and Edgerton, M. (2007) Human Beta-Defensins Kill Candida albicans in an Energy-Dependent and Salt-Sensitive Manner without Causing Menbrane Disruption. Antimicrobial Agents and Chemotherapy, 51, 154-161. http://dx.doi.org/10.1128/AAC.00478-06
|
[25]
|
Fan, S.R., Liu, X.P. and Liao, Q.P. (2008) Human Defensins and Cytokines in Vaginal Lavage Fluid of Women with Bacterial Vaginosis. International Journal of Gynecology & Obstetrics, 103, 50-54. http://dx.doi.org/10.1016/j.ijgo.2008.05.020
|
[26]
|
Krishnakumari, V., Rangaraj, N. and Nagaraj, R. (2009) Antifungal Activities of Human Beta Defensins HBD-1 to HBD-3 and Their c-Terminal Analogs Phd1 to Phd3. Antimicrobial Agents and Chemotherapy, 53, 256-260. http://dx.doi.org/10.1128/AAC.00470-08
|
[27]
|
Levinson, P., Kaul, R., Kimani, J., et al. (2009) Levels of Innate Immune Factors in Genital Fluids: Association of Alpha Defensins and LL-37 with Genital Infections and Increased HIV Acquisition. AIDS, 23, 309-317. http://dx.doi.org/10.1097/QAD.0b013e328321809c
|
[28]
|
Feuerschuette, O.H.M., Silveira, S.K., Feuerschuette, I., Correa, T., Grando, L. and Trepani, Q. (2010) Recurrent Vaginal Candidiasis: Clinical Management. Femina, 38, 31-36. http://files.bvs.br/upload/S/0100-7254/2010/v38n1/a005.pdf
|
[29]
|
Corrales-Garcia, L.L., Possani, L.D. and Corzo, G. (2011) Expression Systems of Human β-Defensins: Vectors, Purification and Biological Activities. Amino Acids, 40, 5-13. http://dx.doi.org/10.1007/s00726-010-0493-7
|
[30]
|
Wallace, M.A., He, J.Q., Burkett, K.M., et al. (2006) Contribution of Alpha and Beta Defensins to Lung Function Decline and Infection in Smokers: An Association Study. Respiratory Research, 7, 76. http://dx.doi.org/10.1186/1465-9921-7-76
|
[31]
|
Ganz, T. (1999) Defensins and Host Defense. Science, 286, 420-421. http://dx.doi.org/10.1126/science.286.5439.420
|
[32]
|
Hackett, C.J. (2003) Innate Immune Activation as a Broad-Spectrum Biodefense Strategy: Prospects and Research Challenges. Journal of Allergy and Clinical Immunology, 112, 686-694. http://dx.doi.org/10.1016/S0091-6749(03)02025-6
|
[33]
|
Castaneda-Casimiro, J., Ortega-Roque, J.A., Venegas-Medina, A.M., et al. (2009) Péptidos antimicrobianos: Péptidos con múltiples funciones. Alergia, Asma e Inmunología Pediátricas, 18, 16-29. http://www.medigraphic.com/pdfs/alergia/al-2009/al091d.pdf
|
[34]
|
Ahn, J.K., Cha, H.S., Lee, J., Jeon, C.H. and Koh, E.M. (2012) Correlation of DEFA1 Gene Copy Number Variation with Intestinal Involvement in Behcet’s Disease. Journal of Korean Medical Science, 27, 107-109. http://dx.doi.org/10.3346/jkms.2012.27.1.107
|
[35]
|
Glenthoj, A., Glenthoj, A.J. and Borregaard, N. (2013) ProHNPs Are the Principal α-Defensins of Human Plasma of Human Plasma. European Journal of Clinical Investigation, 43, 836-843. http://dx.doi.org/10.1111/eci.12114
|
[36]
|
Bastian, A. and Schafer, H (2001) Human Alpha-Defensin 1 (HNP-1) Inhibits Adenoviral Infection in Vitro. Regulatory Peptides, 101, 157-161. http://dx.doi.org/10.1016/S0167-0115(01)00282-8
|
[37]
|
Lehrer, R.I. and Ganz, T. (2002) Defensins of Vertebrate Animals. Current Opinion in Immunology, 14, 96-102. http://dx.doi.org/10.1016/S0952-7915(01)00303-X
|
[38]
|
Kiehne, K., Brunke, G., Meyer, D., Harder, J. and Herzig. K.H. (2005) Oesophageal Defensing Expression during Candida Infection and Reflux Disease. Scandinavian Journal of Gastroenterology, 40, 501-507. http://dx.doi.org/10.1080/00365520510015386
|
[39]
|
Vento, G., Lio, A., Tirone, C., et al. (2013) Association of High Levels of α-Defensins and S100A Proteins with Candida Mannan Detection in Bronchoalveolar Lavage Fluid of Preterm Neonates. Pediatric Research, 74, 19-25. http://dx.doi.org/10.1038/pr.2013.60
|
[40]
|
Raj, P.A., Antonyraj, K.J. and Karunakaran, T. (2000) Large-Scale Synthesis and Functional Elements for the Antimicrobial Activity of Defensins. The Biochemical Journal, 347, 633-641. http://dx.doi.org/10.1042/0264-6021:3470633
|
[41]
|
Fan, S., Liu, X., Wu, C., Xu, L. and Li, J. (2015) Vaginal Nystatin versus Oral Fluconazole for the Treatment for Recurrent Vulvovaginal Candidiasis. Mycopathologia, 179, 95-101. http://dx.doi.org/10.1007/s11046-014-9827-4
|
[42]
|
Fan, S.R. and Liu, X.P. (2011) In Vitro Fluconazole and Nystatin Susceptibility and Clinical Outcome in Complicated Vulvovaginal Candidosis. Mycoses, 54, 501-505. http://dx.doi.org/10.1111/j.1439-0507.2010.01887.x
|
[43]
|
Martins, H.P., da Silva, M.C., Paiva, L.C., Svidzinski, T.I. and Consolaro, M.E. (2012) Efficacy of Fluconazole and Nystatin in the Treatment of Vaginal Candida Species. Acta Dermato-Venereologica, 92, 78-82.
|
[44]
|
Mikamo, H., Matsumizu, M., Nakazuru, Y., Okayama, A. and Nagashima, M. (2015) Efficacy and Safety of a Single Oral 150 mg Dose of Fluconazole for the Treatment of Vulvovaginal Candidiasis in Japan. Journal of Infection and Chemotherapy, 21, 520-526. http://dx.doi.org/10.1016/j.jiac.2015.03.011
|
[45]
|
Fan, S., Liu, X. and Liang, Y. (2015) Miconazole Nitrate Vaginal Suppository 1200 mg versus Oral Fluconazole 150 mg in Treating Severe Vulvovaginal Candidiasis. Gynecologic and Obstetric Investigation, 80. http://dx.doi.org/10.1159/000371759
|
[46]
|
Sobel, J.D. (2015) Recurrent Vulvovaginal Candidiasis. American Journal of Obstetrics & Gynecology. http://dx.doi.org/10.1016/j.ajog.2015.06.067
|
[47]
|
Mendling, W. (2015) Guideline: Vulvovaginal Candidosis (AWMF 015/072), S2k (Excluding Chronic Mucocutaneous Candidosis). Mycoses, 58, 1-15. http://dx.doi.org/10.1111/myc.12292
|